Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	Sirolimus	2	72	flat	flat	BT20 rapamycin 0 2 72	8	1.952	Inf	0.421	0.579	0.0	0.421	0.01	NA	NA	0.421	Inf	0.513	0.513	0.0	0.513	0.01	NA	NA	0.513
Hs 578T	AS605240	3		sigmoid	sigmoid	Hs578T AS-605240 3	8	2.856	63.8	0.588	0.0965	0.826	0.494	1.03	0.983	4.89e-06	NA	5.75	0.518	0.879	0.552	0.465	1.14	0.981	6.87e-06	NA
HCC70	AZD8055	1	72	sigmoid	sigmoid	HCC70 AZD8055 0 1 72	8	1.339	0.0485	0.242	0.442	0.0243	0.26	1.06	0.976	1.32e-05	NA	Inf	0.529	0.721	0.0222	0.54	1.08	0.974	1.81e-05	NA
BT-549	Pictilisib	1	72	sigmoid	sigmoid	BT549 pictilisib 0 1 72	8	1.772	2.08	0.415	0.117	1.42	0.154	0.959	0.987	2.26e-06	NA	5.12	0.541	0.904	1.06	0.396	0.995	0.985	3.49e-06	NA
HCC70	Trametinib	3	72	sigmoid	sigmoid	HCC70 trametinib 0 3 72	8	2.463	Inf	0.56	0.361	0.00419	0.548	0.954	0.95	0.000123	NA	Inf	0.542	0.618	0.00342	0.533	0.965	0.958	7.33e-05	NA
HCC70	AZD8055	2	72	sigmoid	sigmoid	HCC70 AZD8055 0 2 72	8	1.724	0.17	0.404	0.346	0.0331	0.385	0.897	0.996	7.36e-08	NA	Inf	0.543	0.728	0.0284	0.531	0.905	0.996	6.22e-08	NA
BT-20	Everolimus	2	72	flat	flat	BT20 everolimus 0 2 72	8	1.785	Inf	0.426	0.574	0.0	0.426	0.01	NA	NA	0.426	Inf	0.547	0.547	0.0	0.547	0.01	NA	NA	0.547
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	3	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 3 72	8	3.162	Inf	0.654	0.0322	1.18	0.65	4.68	0.99	1.03e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
HCC70	AZD8055	3	72	sigmoid	sigmoid	HCC70 AZD8055 0 3 72	8	2.442	Inf	0.571	0.287	0.0133	0.574	1.17	0.98	8.55e-06	NA	Inf	0.554	0.694	0.0116	0.556	1.17	0.974	1.69e-05	NA
HCC70	AS605240	3	72	sigmoid	sigmoid	HCC70 AS-605240 0 3 72	8	2.447	Inf	0.58	0.112	0.427	0.549	1.18	0.985	3.24e-06	NA	Inf	0.562	0.877	0.345	0.544	1.24	0.982	6.14e-06	NA
HCC70	Trametinib	1	72	sigmoid	sigmoid	HCC70 trametinib 0 1 72	8	1.421	0.015	0.339	0.521	0.00411	0.34	0.879	0.966	4.1e-05	NA	Inf	0.566	0.653	0.00373	0.566	0.875	0.968	3.23e-05	NA
Hs 578T	AZD-6482	2		sigmoid	sigmoid	Hs578T AZD6482 2	8	2.508	6.35	0.602	0.121	74.8	-1.0	0.445	0.998	1.12e-08	NA	6.4	0.573	0.86	6.4	0.0	0.475	0.996	6.36e-08	NA
HCC70	TGX221	2	72	sigmoid	sigmoid	HCC70 TGX-221 0 2 72	8	1.786	1.77	0.467	0.233	0.531	0.227	0.503	0.948	0.000139	NA	5.85	0.575	0.806	3.44	0.0897	0.372	0.937	0.000249	NA
HCC38	ZSTK474	1	72	sigmoid	sigmoid	HCC38 ZSTK474 0 1 72	8	1.742	2.47	0.456	0.132	1.34	0.202	0.843	0.991	7.12e-07	NA	9.02	0.575	0.893	1.0	0.426	0.869	0.99	1.01e-06	NA
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA
HCC70	TGX221	1	72	sigmoid	sigmoid	HCC70 TGX-221 0 1 72	8	1.381	0.539	0.344	0.244	0.245	0.278	1.03	0.986	2.58e-06	NA	Inf	0.578	0.84	0.229	0.536	1.02	0.986	2.87e-06	NA
HCC70	WYE-125132	1	72	sigmoid	sigmoid	HCC70 WYE-132 0 1 72	8	1.382	0.0518	0.346	0.418	0.0175	0.348	1.1	0.985	3.58e-06	NA	Inf	0.579	0.727	0.0165	0.579	1.09	0.983	4.63e-06	NA
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
Hs 578T	Sirolimus	2		flat	flat	Hs578T rapamycin 2	8	2.536	Inf	0.623	0.341	0.0	0.623	0.01	0.16	0.593	0.66	Inf	0.589	0.623	0.0	0.589	0.01	-0.232	1.0	0.624
Hs 578T	Everolimus	2		sigmoid	sigmoid	Hs578T everolimus 2	8	2.550	3210000000.0	0.626	0.335	0.000205	0.476	0.1	0.791	0.00913	NA	18938.0	0.59	0.627	0.000153	0.422	0.1	0.745	0.0166	NA
BT-20	Trametinib	1	72	sigmoid	sigmoid	BT20 trametinib 0 1 72	8	2.016	14.3	0.54	0.225	0.135	0.458	0.534	0.989	1.3e-06	NA	Inf	0.59	0.791	0.0955	0.534	0.545	0.989	1.43e-06	NA
Hs 578T	Everolimus	3		flat	flat	Hs578T everolimus 3	8	2.848	Inf	0.664	0.299	0.0	0.664	0.01	0.475	0.144	0.702	Inf	0.592	0.631	0.0	0.592	0.01	0.486	0.136	0.632
HCC38	ZSTK474	3	72	sigmoid	sigmoid	HCC38 ZSTK474 0 3 72	8	1.458	2.06	0.398	0.146	5.06	-0.41	0.665	0.989	1.23e-06	NA	6.44	0.593	0.898	3.35	0.179	0.678	0.988	1.64e-06	NA

|<
<<
Previous
Page 10 of 18
Next
>>
>
226 to 250 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)